Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Jan 5, 2021Therapix's TheraPEA product has all required Canadian approvals for distributionTherapix Biosciences Ltd. (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced it has entered a...
Dec 8, 2020Therapix Biosciences Ltd. ("Therapix" or the "Company") (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today...
- Dec 2, 2020"In the era of America's deadly opioid crisis, cutting-edge pain therapeutics like THX-160 possess the potential to be a new and effective treatment option for pain patients, reducing the risks of opiate addiction."
Therapix Biosciences Ltd. ("Therapix" or the "Company") (OTC Pink: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today...
- Nov 30, 2020
Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based pharmaceuticals, today released a...
- Nov 19, 2020
Therapix Biosciences Ltd. ("Therapix" or the "Company") (OTC Pink: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today...